PARP1 and ovarian carcinoma: In recent years, the clinical application of PARP inhibitors has brought new light to ovarian cancer patients, which have shown significant long-term survival benefits in a number of clinical studies, such as SOLO-1, PRIMA and PAOLA-1 [4].